OPEN LABEL TRIAL OF AZIMILIDE IN SUPRAVENTRICULAR ARRHYTHMIAS

心房颤动是最常见的心律失常 需要用抗抑郁药治疗， 美国三分之一的心律失常住院病例患者 心房纤颤患者的正常心律被 快速，不规则的心脏跳动，可能会导致一种感觉， 胸闷、气短、胸痛、头晕或丧失 的意识。这些时间段可能持续几分钟或几小时，也可能 除非医生给予紧急治疗，否则无限期持续。的 症状性房颤最常见的治疗方法是 抗抑郁药物治疗目前的药物治疗受到缺乏 疗效、副作用和对这些药物安全性的关注。 本方案的目的是测试 多中心、开放标签协议中的抗疟疾药物阿齐米特， 仅对完成一项随机试验的患者开放 根据CRU方案D87进行。结果尚未公布;后续行动 还在继续

Atrial fibrillation is the most common disorder of the heart rhythm requiring treatment with antiarrhythmic drugs, and it accounts for over one-third of all U.S. hospitalizations for arrhythmias. Patients with atrial fibrillation have their usually normal heart rhythm replaced by periods of rapid, irregular heart beating that may cause a sense of pounding in the chest, shortness of breath, chest pain, dizzyness, or loss of conciousness. These periods may last for minutes or hours, or they may last indefinitely unless acute treatment is given by a physician. The most common treatment for symptomatic atrial fibrillation is antiarrhythmic drug therapy. Current drug therapies are limited by lack of efficacy, side effects and concern over safety of these drugs. This purpose of this protocol is to test the efficacy and safety of the antiarrhythmic drug azimilde in mutl-center, open-label protocols that are open only to patients who have completed one of the randomized trials conducted under CRU protocol D87. Results are not available yet; followup is continuing.